In: European Heart Journal, 2000, vol. 21, no. 21, p. 1776-1784
|
In: European Heart Journal, 2008, vol. 29, no. 4, p. 480-489
|
In: European Heart Journal, 2011, vol. 32, no. 12, p. 1465-1471
|
In: European Journal of Cardio-Thoracic Surgery, 2006, vol. 30, no. 5, p. 814-815
|
In: European Heart Journal, 1989, vol. 10, p. 64-68
|
In: European Journal of Cardio-Thoracic Surgery, 2015, vol. 47, no. 5, p. 860-861
|
In: European Heart Journal, 2011, vol. 32, no. 22, p. 2824-2829
|
In: European Heart Journal, 1995, vol. 16, p. 51-58
|
In: European Heart Journal, 2011, vol. 32, no. 17, p. 2100-2108
|
In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|